Transcutaneous gastric pacing restored gut motility faster in acute pancreatitis patients, partly by reducing elevated vasoactive intestinal peptide (VIP) levels and rebalancing autonomic nerve function.
VIP decreased (p<0.05)Transcutaneous gastric pacing reduced elevated vasoactive intestinal peptide levels, a gut peptide hormone that inhibits motility when elevated in acute pancreatitis
What the researchers found
Transcutaneous gastric pacing (TGP) significantly improved gastrointestinal recovery in early-stage acute pancreatitis patients compared to conventional treatment. The TGP group had shorter time to first bowel movement (p<0.05) and fewer hospital days (p<0.05). Mechanistically, TGP decreased serum vasoactive intestinal peptide (VIP) levels (p<0.05), increased normal gastric slow waves (p<0.05), and reduced the inflammatory marker IL-6 (p<0.05).
Autonomic nervous system testing revealed TGP increased vagal (parasympathetic) activity while decreasing sympathetic activity (both p<0.01), suggesting the treatment works by restoring autonomic balance through vagal stimulation, which in turn normalizes gastrointestinal peptide signaling.
Why it matters
Acute pancreatitis frequently disrupts gut motility, prolonging hospitalization and worsening outcomes. Current treatments are largely supportive. This study shows that a non-invasive electrical stimulation device can restore gut function faster, and reveals that the mechanism involves normalization of gastrointestinal peptide hormones — specifically reducing VIP, which inhibits gut motility when elevated. Understanding this peptide-mediated mechanism could lead to better targeted therapies for gut motility disorders.
The numbers in context
n=65 · Shorter first defecation time (p<0.05) · Fewer hospital days (p<0.05) · VIP decreased (p<0.05) · Normal gastric slow waves increased (p<0.05) · IL-6 decreased (p<0.05) · Vagal activity (HF) increased (p<0.01) · Sympathetic activity (LF) decreased (p<0.01)
How the study worked
Sixty-five patients with early-stage acute pancreatitis were randomly assigned to conventional treatment or conventional treatment plus transcutaneous gastric pacing. Researchers measured serum ghrelin and VIP (peptide hormones), electrogastrogram parameters (gastric electrical activity), time to first bowel movement, hospital stay length, IL-6 inflammatory markers, and heart rate variability to assess autonomic nervous system function.
Who was studied
65 early-stage acute pancreatitis patients
What this study cannot tell us
The sample size is relatively small (65 patients). The abstract does not report blinding, which could introduce placebo effects — patients in the TGP group knew they were receiving the device. Ghrelin levels were measured but not reported as significantly different, limiting the peptide mechanism story. The study was conducted at a single center, and longer-term outcomes were not assessed.
How to read the evidence
This is a randomized controlled trial, which provides moderate evidence strength. However, the small sample size (65 patients), single-center design, and unclear blinding protocol limit the certainty of the findings. The results are promising but need replication in larger, blinded trials.
When this study was published
Published in 2024, this study represents current research into neuromodulation approaches for gut motility disorders and their effects on gastrointestinal peptide hormones.
The bigger picture
Gastrointestinal motility disorders affect patients with many conditions beyond pancreatitis, including post-surgical ileus, gastroparesis, and critical illness. Understanding how non-invasive neuromodulation affects gut peptide hormones like VIP and ghrelin could open the door to peptide-targeted therapies for a wide range of gut motility problems. This study adds to growing evidence that the gut-brain axis — mediated by peptide hormones and autonomic nerves — can be therapeutically manipulated.
Questions still open
- Would transcutaneous gastric pacing be effective for other conditions with impaired gut motility, such as gastroparesis or post-surgical ileus?
- Could VIP levels serve as a biomarker to predict which patients will benefit most from gastric pacing therapy?
- What is the optimal duration and frequency of gastric pacing sessions for maximum peptide hormone normalization?
Common questions
What is vasoactive intestinal peptide (VIP) and why does it matter in pancreatitis?
How does transcutaneous gastric pacing work?
Read the original research
The mechanism of transcutaneous gastric pacing treatment on gastrointestinal motility recovery and inflammation improvement in early-stage acute pancreatitis patients.
BMC gastroenterology, 24(1), 407
Citation
Jia, Zhenyu; Kong, Lingchao; Lu, Xiaochun; Lu, Jianying; Shen, Yuying; Qiao, Zhenguo; Xia, Tingting. (2024). The mechanism of transcutaneous gastric pacing treatment on gastrointestinal motility recovery and inflammation improvement in early-stage acute pancreatitis patients.. BMC gastroenterology, 24(1), 407. https://doi.org/10.1186/s12876-024-03498-z